Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22149284 | 1.00 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL12712866 | 0.91 | CA2 (0.38) | CA1CA2CA9 | |
| SCHEMBL277481 | 0.91 | CA2 (0.38) | CA1CA2CA9 | |
| SCHEMBL321709 | 0.91 | CA2 (0.38) | CA1CA2CA9 | |
| SCHEMBL13053720 | 0.91 | CA2 (0.38) | CA1CA2CA9 | |
| SCHEMBL2802528 | 0.76 | — | — | |
| SCHEMBL18457371 | 0.75 | CA1 (0.40) | CA1CA2CA9 | |
| SCHEMBL7149970 | 0.75 | CA1 (0.40) | CA1CA2CA9 | |
| SCHEMBL13053771 | 0.73 | CA1 (0.34) | CA1CA2CA9 | |
| SCHEMBL13954220 | 0.72 | CA1 (0.32) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| WO-2020127194-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | CA1 3322/4885CA2 3241/4885CA9 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.